100
80
60
40
20
0
Appearance free rate (%)
0
6
12
18
27
24
21
3
9
15
1
Alectinib
Crizotinib
Time (months)
No. of patients at risk
39
28
22
12
63
48
28
16
5
3
80
63
89
75
89
74
100
80
60
40
20
0
Progression free rate (%)
0
6
12
18
27
24
21
3
9
15
1
Alectinib
Crizotinib
Time (months)
No. of patients at risk
9
11
5
2
13
17
8
5
4
1
13
23
14
29
14
28
1
Alectinib (N=89)
Crizotinib (N=75)
Event
3 (3.4%)
11 (14.7%)
Median [95% CI]
- [- ; -]
- [15.7 ; -]
P-Value
0.0019
HR [95% CI]
0.17 [0.05 ; 0.60]
Alectinib (N=14)
Crizotinib (N=29)
Event
1 (7.1%)
10 (34.5%)
Median [95% CI]
- [- ; -]
- [8.3 ; -]
P-Value
0.0492
HR [95% CI]
0.16 [0.02 ; 1.28]
Alectinib
Crizotinib
Alectinib
Crizotinib
Time to appearance of CNS disease
without CNS disease at BL
Time to progression of CNS disease
with CNS disease at BL
Kim Y-H, et al. WCLC 2016
1L ALECTINIB: J-ALEX
